SCHEMBL23701489

SCHEMBL23701489

COC(C)Oc1ccccn1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 4/20 0.41
LMNA P02545 3/20 0.41
CCR1 P32246 2/20 0.41
CCR5 P51681 2/20 0.41
CCR8 P51685 2/20 0.41
CYP1A2 P05177 2/20 0.41
POLB P06746 1/20 0.41
METAP1 P53582 1/20 0.41
BLM P54132 1/20 0.41
HIF1A Q16665 1/20 0.41
DOHH Q9BU89 1/20 0.41
P4HTM Q9NXG6 1/20 0.41
SMN1; SMN2 Q16637 3/20 0.38
NPC1 O15118 3/20 0.38
RAB9A P51151 2/20 0.38
TRPM8 Q7Z2W7 1/20 0.36
TP53 P04637 2/20 0.35
ALOX15 P16050 2/20 0.35
HTT P42858 2/20 0.35
L3MBTL1 Q9Y468 2/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3645535 0.91 KDM4E (0.44) KDM4ELMNACCR1CCR5CCR8
SCHEMBL29388428 0.83 KDM4E (0.44) KDM4ELMNACCR1CCR5CCR8
SCHEMBL826368 0.83 KDM4E (0.44) KDM4ELMNACCR1CCR5CCR8
SCHEMBL5281969 0.79 SMN1; SMN2 (0.41) KDM4ELMNACCR1CCR5CCR8
SCHEMBL2307870 0.79 KDM4E (0.41) KDM4ELMNACCR1CCR5CCR8
SCHEMBL20995459 0.79 KDM4E (0.41) KDM4ELMNACCR1CCR5CCR8
SCHEMBL4632146 0.79 KDM4E (0.41) KDM4ELMNACCR1CCR5CCR8
SCHEMBL11001241 0.79 SMN1; SMN2 (0.41) KDM4ELMNACCR1CCR5CCR8
SCHEMBL12846287 0.79 KDM4E (0.41) KDM4ELMNACCR1CCR5CCR8
SCHEMBL27945113 0.79 KDM4E (0.41) KDM4ELMNACCR1CCR5CCR8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210238159-A1 Modulators of the Cystic Fibrosis Transmembrane Conductance Regulator Protein and Methods of Use ABBVIE GLOBAL LIMITED (BM) 2021-08-05 US disclosed
CN-102574845-A 1h-imidazo[4,5-c]quinolinone derivatives NOVARTIS AG 2012-07-11 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210238159-A1 Modulators of the Cystic Fibrosis Transmembrane Conductance Regulator Protein and Methods of Use CFTR, SLC47A1, SCNN1A KDM4E 3854/4885LMNA 3152/4885CCR1 728/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.